Gapping up
In reaction to strong earnings/guidance: SCTY +7.4% (continues to expect to achieve 278 MW deployed for its current fiscal year 2013), ANGO +6.4%, SWY +5.8%, (upgraded to Overweight from Neutral at JPMorgan ), INFY +5.4%, JPM +1.6%, CHMT +0.6% (announces agreement to sell consumer products segment to KIK Custom Products for $315 mln; commences exploration of sale of agrochemicals business; sees Q3 earnings below consensus), WFC +0.5%.
M&A related: TWGP +6.4% (WSJ discusses Tower Group's bankers are exploring sale of the company; upgraded to Buy from Neutral at Guggenheim), .
Select financial related names showing strength: IRE +3.3%, HBC +1.6%, CS +1.5%, C +1.4%, BNS +1.4%, KEY +1.3%, BAC +1.2%, DB +0.7%, GS +0.6% .
A few solar names are trading higher: RSOL +5.1%, CSIQ +3.8%, HSOL +3.2%, YGE +2.4%, JASO +1.5%, JKS +1.3%,
India related names seeing premarket upside: TTM +3.5%, IBN +2.7%, HDB +2.4%,
Other news: OSIR +24.9% (announces agreement for culture-expanded MSCs including Prochymal worth up to $100 mln plus royalties), SSW +22% (disclosed that it will no longer proceed with its previously announced public offerings of common shares and convertible notes as it would not be in the best interests of our shareholder), OCLR +7% (II-VI announces agreement to purchase Oclaro's Fiber Amplifier and Micro-Optics business in a transaction valued at $88.6 mln; announces resignation of Jerry Turin, CFO), IMGN +5.7% (still checking), SRPT +4.9% (still checking), SRPT +4.9% (Sarepta Therapeutics to host webcast and conference call for the Duchenne Muscular Dystrophy Community on October 17 at 12pm ET), VVUS +2.8% (Auxilium Pharma announces license agreement for the marketing rights to STENDRA in the US and Canada), SAP +2.2% (still checking), SAIA +1.4% ( SAIA to replace GPOR int he S&P SmallCap 600), FXCM +1.4% (FXCM to replace KDN in the S&P SmallCap 600), BBRY +1.2% (ongoing M&A speculation), CTSH +1.1% (following INFY results), OUTR +0.8% (following Jana Partners' Barry Rosenstein comments on CNBC), GILD +0.4% (Gilead Sciences lifting on positive Barron's mention), GPN +0.4% ( disclosed accelerated share repurchase program with Goldman).
Analyst comments: PHG +2.8% (upgraded to Buy from Neutral at Goldman), CTXS +2.1% (upgraded to Neutral from Underweight at JPMorgan), JNJ +1.3% (upgraded to Neutral from Sell at Goldman), DEO +0.6% (upgraded at Exane BNP Paribas)